0.00Open0.05Pre Close0 Volume495 Open Interest7.00Strike Price0.00Turnover0.00%IV105.24%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-3DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma68.70Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced that the FDA has lifted the clinical hold on its Phase 1 clinical trial of AMX0114, an antisense oligonucleotide targeting calpain-2 for ALS treatment. The company will proceed with opening U.S. sites for screening, enrollment, and dosing.
The Phase 1 LUMINA cl...
No comment yet